Consilium Strategic Communications Advises Hyloris Pharmaceuticals on its Successful Initial Public Offering

Euronext Brussels listing of innovative specialty pharmaceutical company, raises minimum of EUR 62 million

London, 3 July 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is delighted to have advised on the successful initial public offering (IPO) of Hyloris Pharmaceuticals SA on Euronext Brussels. The offering raised EUR 62 million which could be increased to EUR 71 million if the overallotment is fully exercised.

Hyloris Pharmaceuticals is based in Liège, Belgium, and is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. By developing proprietary products, the company believes it offers significant advantages compared to currently available alternatives.

The Consilium team was led by Amber Fennell and supported by Chris Welsh, Ashley Tapp, Lucy Featherstone, Carina Jurs, Alex Bridge and Taiana De Ruyck Soares in Belgium. Consilium continues to advise the company on its financial communications and investor relations as a publicly listed company. KBC Securities and Kempen & Co acted as Joint Global Coordinators and Joint Bookrunners in the offering.

Funds raised from the IPO will be used for the development of Hyloris’ existing portfolio of product candidates, the establishment of a commercial team in the United States for its IV Cardiovascular portfolio, to fund the expansion of the pipeline both internally and through business development opportunities, and for general corporate purposes.

Commenting on the successful IPO of Hyloris Pharmaceuticals, Amber Fennell, Partner and Co-Founder of Consilium Strategic Communications, said: “We are delighted to have supported Hyloris through its successful listing on Euronext Brussels and to have assisted Stijn and his team in navigating some of the challenges of communicating with investors during the COVID-19 pandemic. We look forward to continuing to support the business as they commence their journey as a listed company.”

Stijn Van Rompay, Chief Executive Officer at Hyloris Pharmaceuticals, said: “We are grateful for the strong level of support and guidance provided by Consilium throughout the IPO process. The Consilium team has been a huge support in providing us with professional and agile advice, and the team at Hyloris looks forward to continuing our work with Consilium as we establish the company on Euronext Brussels.”